Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes

被引:199
作者
Kane, Bartholomew J.
Zinner, Michael J.
Yarmush, Martin L.
Toner, Mehmet
机构
[1] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Serv, Boston, MA 02114 USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA
[4] Shriners Hosp Children, Boston, MA 02114 USA
关键词
D O I
10.1021/ac051856v
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Nearly half a billion dollars in resources are lost each time a drug candidate is withdrawn from the market by the Food and Drug Administration (FDA) for reasons of liver toxicity. The number of late-phase drug developmental failures due to liver toxicity could potentially be reduced through the use of hepatocyte-based systems capable of modeling the response of in vivo liver tissue to toxic insults. With this article, we report progress toward the goal of realizing an array of primary hepatocytes for use in high-throughput liver toxicity studies. Described herein is the development of a 64 ( 8 x 8) element array of microfluidic wells capable of supporting micropatterned primary rat hepatocytes in coculture with 3T3-J2 fibroblasts. Each of the wells within the array was continuously perfused with medium and oxygen in a nonaddressable format. The key features of the system design and fabrication are described, including the use of two microfluidic perfusion networks to provide the coculture with an independent and continuous supply of cell culture medium and oxygen. Also described are the fabrication techniques used to selectively pattern hepatocytes and 3T3-J2 fibroblasts within the wells of the array. The functional studies used to demonstrate the synthetic and metabolic capacity of the array are outlined in this article. These studies demonstrate that the hepatocytes contained within the array are capable of continuous, steady-state albumin synthesis (78.4 mu g/day, sigma = 3.98 mu g/ day, N = 8) and urea production (109.8 mu g/day, sigma = 11.9 mu g/day, N) 8). In the final section of the article, these results are discussed as they relate to the final goal of this research effort, the development of an array of primary hepatocytes for use in physiologically relevant toxicology studies.
引用
收藏
页码:4291 / 4298
页数:8
相关论文
共 32 条
  • [1] MAINTENANCE AND INDUCTION IN COCULTURED RAT HEPATOCYTES OF COMPONENTS OF THE CYTOCHROME-P450-MEDIATED MONOOXYGENASE
    AKRAWI, M
    ROGIERS, V
    VANDENBERGHE, Y
    PALMER, CNA
    VERCRUYSSE, A
    SHEPHARD, EA
    PHILLIPS, IR
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (08) : 1583 - 1591
  • [2] PROLONGED MAINTENANCE OF ACTIVE CYTOCHROME-P-450 IN ADULT-RAT HEPATOCYTES CO-CULTURED WITH ANOTHER LIVER-CELL TYPE
    BEGUE, JM
    GUGUENGUILLOUZO, C
    PASDELOUP, N
    GUILLOUZO, A
    [J]. HEPATOLOGY, 1984, 4 (05) : 839 - 842
  • [3] Probing heterotypic cell interactions: Hepatocyte function in microfabricated co-cultures
    Bhatia, SN
    Balis, UJ
    Yarmush, ML
    Toner, M
    [J]. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 1998, 9 (11) : 1137 - 1160
  • [4] Microfabrication of hepatocyte/fibroblast co-cultures: Role of homotypic cell interactions
    Bhatia, SN
    Balis, UJ
    Yarmush, ML
    Toner, M
    [J]. BIOTECHNOLOGY PROGRESS, 1998, 14 (03) : 378 - 387
  • [5] Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells
    Bhatia, SN
    Balis, UJ
    Yarmush, ML
    Toner, M
    [J]. FASEB JOURNAL, 1999, 13 (14) : 1883 - 1900
  • [6] Bhatia SN, 1997, J BIOMED MATER RES, V34, P189, DOI 10.1002/(SICI)1097-4636(199702)34:2<189::AID-JBM8>3.0.CO
  • [7] 2-M
  • [8] BHATIA SN, 1999, ASME HDT, V37, P99
  • [9] MICROPATTERNING PROTEINS AND SYNTHETIC PEPTIDES ON SOLID SUPPORTS - A NOVEL APPLICATION FOR MICROELECTRONICS FABRICATION TECHNOLOGY
    BRITLAND, S
    PEREZARNAUD, E
    CLARK, P
    MCGINN, B
    CONNOLLY, P
    MOORES, G
    [J]. BIOTECHNOLOGY PROGRESS, 1992, 8 (02) : 155 - 160
  • [10] The price of innovation: new estimates of drug development costs
    DiMasi, JA
    Hansen, RW
    Grabowski, HG
    [J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185